Virbac Posts 7.4% Organic Revenue Growth, 18.8% EBIT Margin in H1…

Event summary

Virbac reported H1 2026 revenue growth of 7.4% at constant exchange rates, with adjusted EBIT margin expanding to 18.8% from 18.3% in H1 2025.
Companion animal segment grew 10.0%, while farm animal segment increased 6.7%, driven by Supercharge platforms (excluding Thyronorm) up 12%.
Net debt rose to €196 million from €173 million due to seasonal working capital requirements.
2026 guidance confirmed at the upper end of the range: 5.5% to 7.5% revenue growth and ~17% adjusted EBIT margin.

The big picture

Virbac's strong H1 2026 performance reflects its strategic focus on high-margin specialty assets and operational efficiency. The company's ability to navigate geopolitical risks and sustain integration momentum will be critical as it targets the upper end of its 2026 guidance. The animal health sector continues to prioritize innovation and cost management, with Virbac positioning itself as a leader in both areas.

What we're watching

Integration Success: Whether Virbac can sustain the momentum from Thyronorm integration and Supercharge platform growth.
Operational Efficiency: The pace at which Virbac's global COGS efficiency program offsets inflationary pressures.
Geopolitical Risks: How evolving Middle East tensions may impact Virbac's supply chain and revenue.